8 funding opportunities found in this category. Change the order of results:
Lowest Award to Highest
Highest Award to Lowest
Foundation for Anesthesia Education and Research Mentored Research Training Grants
Applications due February 15, 2014
Mentored Research Training Grants help anesthesiologists develop the skills, preliminary data for subsequent grant applications and research publications needed to become independent investigators.
The MRTG is a two-year, $175,000 award that provides funding to faculty members who have completed their core anesthesiology residency training within the past 10 years. Year one is funded up to $75,000, and year two is funded up to $100,000. The MRTG requires 75 percent protected non-clinical time for research.
Areas of Research
The proposed project must be in basic science, clinical or translational, or health services research.
Mentored Research Training Grant – Basic Science
Studies pertaining to any of the fundamental questions broadly related to anesthesiology. Typically laboratory experiments with cells or animals.
Mentored Research Training Grant – Clinical or Translational
Research conducted with human subjects, or on material of human origin such as tissues, specimens and cognitive phenomena, for which the investigator directly interacts with human subjects. It includes mechanisms of human disease, therapeutic interventions, clinical trials and/or development of new technologies. Studies would typically require approval from the local institutional review board.
Mentored Research Training Grant – Health Services Research
Outcomes and health services research examines how people obtain access to health care, the cost of care and what happens to patients as a result of this care. The main goals of health services research are to identify the most effective ways to organize, manage, finance and deliver high quality care. This grant is jointly sponsored with the Anesthesia Quality Institute.
At the time of the award, applicants must meet the following eligibility requirements.
• U.S. citizen, permanent U.S. resident, or holder of H-1 visa with minimum of three years remaining. A J-1 visa holder would not qualify.
• Graduate physician with an unexpired, permanent, unconditional and unrestricted license to practice medicine or osteopathy in at least one state or jurisdiction of the United States.*
• No more than 10 years from completion of initial core anesthesiology residency training, whether or not from an ACGME-accredited program.*
For 2014 applications, core anesthesiology residency training graduation/completion year must be 2004 or later.
• Certified by the American Board of Anesthesiology or in the examination system.*
• Active member of the American Society of Anesthesiologists.
The MRTG is not intended for investigators who have received significant extramural funding, such as NIH R-awards, K23, K08, K12, KL2 or AHA Young Investigator Awards. FAER does not allow for concurrent funding of an MRTG with these or similar awards.
The MRTG is not intended for established investigators who are changing areas of interest.
*The FAER Grant Management Committee will consider applicants with equivalent training or certification on a case-by-case basis. Submit questions regarding eligibility to Jody Clikeman, Program Coordinator, at JodyClikeman [at] faer.org. Note that you may be asked to submit a curriculum vitae or other supporting documentation for the committee’s review.
• During the two years of FAER-funded research, the recipient must devote a minimum commitment equivalent of nine calendar person months — 75 percent of the PI’s full-time appointment — to research and career development activities directly related to the FAER-funded project. (These activities may not necessarily be included in the specific aims of the FAER research plan.)
• The percent effort on the FAER-funded research and the percent of time on career development activities should be described in the budget justification.
• The remaining 25 percent effort can be divided among clinical and teaching activities only if these activities are consistent with the recipient’s development into an independent anesthesiologist clinician-scientist or health services researcher.
• The total funding amount for a Mentored Research Training Grant is $175,000.
• Year one will be paid up to $75,000. Year two will be paid up to $100,000.
• Quarterly grant payments are made to the institution, not directly to the award recipient.
• Award renewal for the second year is contingent on the FAER Board of Directors’ favorable review of the interim report.
Contact Jody Clikeman, grants program coordinator, at 507-266-6866 or JodyClikeman[at]faer.org.
Request for Applications: Innate Immune System Impact
The Simons Foundation Autism Research Initiative (SFARI) seeks to improve the diagnosis and treatment of autism spectrum disorders by funding innovative research of the highest quality and relevance.
Objective of the Innate Immune System Impact Award
Grants awarded through this Request for Applications (RFA) are intended to advance our understanding of the impact of activation of the innate immune system on behavioral, circuit, synaptic and neuronal functions in order to understand the consequences of infection and immune activation on autism-related behaviors.
To this end, we seek applications for investigations of the impact of physiologically relevant activation of the innate immune system on behavioral, circuit, synaptic and neuronal functions in animal models of autism. SFARI especially encourages applications that address either of the following two issues:
(1) Effects of activation of the maternal innate immune system on embryonic central nervous system development in genetic models of autism and controls. How do fetal genetics and maternal innate immune activation interact to affect postnatal autism-related phenotypes, and what are the mechanisms through which they interact?
(2) Effects of activation of the innate immune system in genetic autism models and adult controls. How does innate immune activation affect behavioral, circuit, synaptic and cellular function in these genetic models and in controls? What are the roles of cytokine signaling, fever, immune cell activation and other effectors on these functions?
SFARI prioritizes animal models with strong construct validity based on human genetic studies of autism. To this end, SFARI is currently funding systematic behavioral testing on select mouse models and increasing their availability to the broader scientific community through The Jackson Laboratory in Bar Harbor, Maine. Investigators are strongly encouraged to consider using this resource when developing their experimental plans. Given the breadth of knowledge about the genetics of autism, SFARI expects and encourages most applicants to focus on genetic autism and/or innate immunity mouse models, but other models may be proposed if the application contains a compelling rationale based on strong evidence from human studies.
Eligibility and collaboration
All applicants and key collaborators must hold a Ph.D., M.D. or equivalent degree and have a faculty position or the equivalent at a college, university, medical school or other research facility. Applications may be submitted by domestic and foreign nonprofit organizations; public and private institutions, such as colleges, universities, hospitals, laboratories, units of state and local government; and eligible agencies of the federal government. There are no citizenship or national residence requirements.
If the proposal includes investigators at more than one site, all investigators should have demonstrated prior success in similar collaborations.
Funding period and budget
The grant period is for three (3) years. Continued funding is possible, when justified by scientific progress. During this initial three-year period, SFARI plans to commit up to $1 million annually to support projects funded as a result of this RFA.
Applications should include the following:
1. Narrative, not exceeding six (6) pages (excluding references and figures). Proposals should include specific aims, background relevant to the application, significance of the proposed studies, preliminary results, experimental design, pitfalls and alternative strategies, relevance to autism, and a timeline with milestones.
2. Biosketches for Principal Investigator(s) and Key Collaborators. The investigative team should include members with strong expertise in the physiological recordings and behaviors they propose in their application.
3. Current and pending support for Principal Investigator(s) and Key Collaborators.
4. Budget. While there are no budget caps on the individual applications, budgets will strongly factor into the competitiveness of an application. Budgets of more than $250,000 annually will need convincing justification. It is unlikely that SFARI will make an award larger than this amount. Proposals should include a realistic budget sufficiently detailed for evaluation of needed resources. SFARI will work closely with investigative teams with competitive applications to arrive at a suitable budget. Indirect costs are limited to 20 percent of the modified total direct costs.
Applications with multiple Principal Investigators from different institutions that would like to be paid separately must include a signed budget template and budget justification for each Principal Investigator’s institution. Applications with subcontracts must include a budget and budget justification. The budget template and budget justification are available for download in the proposal attachments section of proposalCENTRAL’s full application.
5. Research environment and resources. Investigators should demonstrate access to appropriate resources for high-capacity data collection and analysis, although SFARI will work with awarded investigative teams to provide additional informatics support as needed.
6. Data-sharing plan. The plan should include sharing of raw and analyzed data. SFARI will work closely with awarded investigative teams to ensure that the final plan includes timely dissemination of data with reasonable embargo provisions.
For more details, see the Instructions document, which is available for download in the proposal attachments section of proposalCENTRAL.
The deadline for full proposal submission is 3 March 2014, 5 p.m. Eastern. No extensions will be given. If you have any difficulties, please contact email@example.com.
Competitive applications will receive external peer review. SFARI will make final funding decisions; notification of award is expected by 1 July 2014, with funding expected to begin 1 August 2014.
Instructions for submission
Applications must be completed electronically and submitted using forms provided at proposalCENTRAL. Please log in as an applicant, scroll to ‘Simons Foundation’ and click on the program.
Glenn/American Federation for Aging Research Scholarships for Research in the Biology of Aging
The deadline for applications for the 2014 awards is January 15, 2014.
In order to continue to attract new generations of talented investigators, the Glenn/AFAR Scholarships for Research in the Biology of Aging have been established. The program is designed to give students enrolled in MD, DO, PhD, or combined-degree programs the opportunity to conduct a three-to-six-month research project focused on biomedical research in aging. The program aims to give students the chance to learn more about the field of aging research, as well as increase their understanding of the challenges involved in improving the quality of life for older people.
Up to ten scholarships will be awarded in 2014. They will enable PhD, MD, and DO candidates at any level to undertake a three-to-six-month research project on a subject related to the basic sciences and aging. Students are encouraged to make their proposals as focused as possible – the strongest projects are those that focus on a particular subject area. Clinical, epidemiology, health services, and outcome projects will not be considered. Examples of promising areas of research include, but are not limited to:
• Aging and immune function
• Stem Cell Aging
• Genetic Control of longevity
• Neurobiology and neuropathology of aging
• Invertebrate or vertebrate animal models
• Cardiovascular aging
• Aging and cellular stress response
• Metabolic and endocrine changes
• Age-related changes in cell proliferation
• Caloric restriction and aging
• DNA repair and control of gene expression
• Biology of the menopause
• Aging and apoptosis
• Biodemographic analysis of aging
• Comparative gerontology
• Evolutionary biological aspects of the biology of aging
• Macular degeneration
• Regenerative biology
• RNA control of gene expression in relation to age-related diseases
The research project must be carried out under the supervision of a faculty mentor. It may be carried out in any not-for-profit setting, such as universities, medical schools, hospitals, or non-government agencies. Applicants who also receive NIH, NSF or DOD stipend support are eligible to receive the Glenn/AFAR Scholarship. However, recipients cannot hold any other awards or scholarships concurrently with the Glenn/AFAR Scholarship. Each scholarship carries an award of $5,000. No indirect costs or overhead are allowed. Award recipients will be invited to attend the 2014 AFAR Grantee Conference.
Applicants must be MD, DO, PhD, or combined degree students in good standing at a not-for-profit institution in the United States. If accepted, applicants will be asked to submit a Proof of Enrollment form confirming their enrollment at a U.S. institution. Applicants may not hold another award or participate in another scholarship program concurrently with the Glenn/AFAR Scholarship.
Applications will be evaluated by an AFAR Scientific Committee on the basis of:
• The qualifications and ability of the applicant, as demonstrated by academic performance, statement of purpose, and letter of reference
• The merit and feasibility of the proposed research project and its relevance to aging
• The qualifications of the designated mentor, his or her endorsement of the research project, assurance of active supervision, and demonstrated commitment to aging research and to the student
• Likelihood that the project will advance the applicant’s interest and career in aging research
• Quality of the research environment
The deadline for receipt of all applications and supporting materials is January 15, 2014 at 5:00 p.m. EST.
Applicants will be notified on funding decisions or around April 30, 2014. If funded, the project start date must be before December 31, 2014.
The Scholarship recipients will be required to submit a full report detailing their research methods and findings within 90 days of completing the research projects. Similarly, the mentor will be required to provide an evaluation of the student’s performance and impressions of the impact of the program on the student’s career.
The award recipients are expected to attend the AFAR Grantee Conference which convenes AFAR grant recipients and leaders in the field to review and disseminate the research progress and findings of the grantees. The meeting encourages networking, facilitates collaboration, and enhances the development of leadership.
Glenn/American Federation for Aging Research Breakthroughs in Gerontology Award
Sponsored by The Glenn Foundation for Medical Research, in collaboration with the American Federation for Aging Research (AFAR), the "Breakthroughs in Gerontology" (BIG) initiative provides timely support to a small number of pilot research programs that may be of relatively high risk but which offer significant promise of yielding transforming discoveries in the fundamental biology of aging. The hope is that one or more of the funded research projects will lead to major new insights into the molecular factors that coordinate aging in multiple cells and tissues, and the ways in which the aging process is differentially timed in long-lived species.
Projects that focus on genetic controls of aging and longevity, on delay of aging by pharmacological agents or dietary means, or which elucidate the mechanisms by which alterations in hormones, anti-oxidant defenses, or repair processes promote longevity are all within the intended scope of this competition. Projects that focus on specific diseases or assessment of health care strategies will receive lower priority, unless the research plan makes clear and direct connections to fundamental issues in the biology of aging. Studies of invertebrates, mice, human clinical materials or cell lines are eligible for funding. Although preliminary data are always helpful for evaluating the feasibility of the experiments proposed, the emphasis in review will be on creativity and the likelihood that the findings will lead to improved understanding that merits follow-up studies.
Recipients of this award are expected to attend the AFAR Grantee Conference. The purpose of the meeting is to promote scientific and personal exchanges among recent AFAR grantees and experts in aging research.
To be eligible, applicants must at the time they submit their proposal be full-time faculty members at the rank of Assistant Professor or higher. A strong record of independent publication beyond the postdoctoral level is a requirement. Applications from individuals not previously engaged in aging research are particularly encouraged, as long as the research proposals show high promise for leading to important new discoveries in biological gerontology.
Individuals who are employees in the NIH Intramural program are not eligible. The proposed research must be conducted at any type of not-for-profit setting in the United States. Former AFAR Research Grant awardees may apply. If you are applying for a 2014 AFAR Research Grant, you may not also apply for the 2014 Glenn/AFAR BIG Award.
Questions about eligibility and suitability of research project can be addressed to firstname.lastname@example.org.
Applications are reviewed based on the following criteria:
Qualifications of the applicant
Quality and promise of the proposed research and relevance to aging
Excellence of the research environment
The deadline of receipt of the Letters of Intent (LOI) is December 16, 2013 at 5:00 p.m. EST. Please refer to the Glenn/AFAR BIG LOI for instructions. Incomplete or improperly completed LOIs cannot be considered. All LOIs should be submitted as PDFs through the website www.afar.org/grants/. The Letters of Intent will be reviewed by a committee. Applicants will be notified by January 31, 2014, and a subset of applicants will be invited to submit a full application. The deadline for receipt of full applications is March 17, 2014.
Two two-year awards will be made in 2014, at the level of $200,000 total ($100,000 per year), of which up to 8% may be used for institutional overhead. The amount and the duration of the award may be modified if during the review process or at the funding stage it is evident that such modifications would better serve the objectives of the program.
All LOI candidates who are invited to submit applications must have it endorsed by their institution. Final awards are announced by early June. The award start date is July 1, 2014. AFAR will not provide reviewer critiques to any applicants at any review level.
Investigators will be required to submit a brief narrative report on the progress of their research. Final narrative and financial reports are required within three months following the end date of the award.
American Federation for Aging Research Research Grants for Junior Faculty
AFAR provides up to $100,000 for a one- to two-year award to junior faculty (M.D.s and Ph.D.s) to conduct research that will serve as the basis for longer term research efforts. AFAR-supported investigators study a broad range of biomedical and clinical topics including the causes of cellular senescence, the role of estrogen in the development of osteoporosis, the genetic factors associated with Alzheimer's disease, the effects of nutrition and exercise on the aging process, and much more. Since 1981, over 680 AFAR Research Grants have been awarded.
The major goal of this program is to assist in the development of the careers of junior investigators committed to pursuing careers in the field of aging research. AFAR supports research projects concerned with understanding the basic mechanisms of aging. Projects investigating age-related diseases are also supported, especially if approached from the point of view of how basic aging processes may lead to these outcomes. Projects concerning mechanisms underlying common geriatric functional disorders are also encouraged, as long as these include connections to fundamental problems in the biology of aging. Projects that deal strictly with clinical problems such as the diagnosis and treatment of disease, health outcomes, or the social context of aging are not eligible.
Examples of potentially fundable areas of research include, but are not limited to:
Aging and immune function
Stem Cell Aging
Genetic Control of longevity
Neurobiology and neuropathology of aging*
Mechanisms of dementia*
Invertebrate or vertebrate animal models
Aging and cellular stress response
Metabolic and endocrine changes
Age-related changes in cell proliferation
Caloric restriction and aging
DNA repair and control of gene expression
Biology of the menopause
Aging and apoptosis
Biodemographic analysis of aging
Evolutionary biological aspects of the biology of aging
*Applicants proposing a project in Alzheimer's Disease or healthy brain aging research should apply for the New Investigator Awards in Alzheimer's Disease. Applicants proposing other dementia-related research should apply for the AFAR Research grant.
It is anticipated that approximately 10 grants of up to $100,000 each will be awarded in 2014. Applicants may propose to use the award over the course of one or two years as justified by the proposed research. Up to 8% of funds may be budgeted for overhead or indirect costs (not to exceed $7,407). Funding will begin July 1, 2014.
The applicant must be an independent investigator with independent research space as described in a form completed by the Dean or Department Chair, and must be no more than 10 years beyond start of postdoctoral research training as of July 1, 2014. Exceptions to the ten year rule may be requested for unusual circumstances by emailing an NIH-style biosketch to AFAR at email@example.com.
The AFAR Research Grant Program does not provide support for:
Postdoctoral fellows in the laboratory of a senior investigator
Investigators who have already received major extramural funding for research (such as an R01 or NSF equivalent grant)
Senior faculty, i.e. at the rank of Associate Professor level or higher
Former AFAR Research Grant recipients
NIH Intramural program employees
Applicants for the 2014 Glenn/AFAR Breakthrough in Gerontology (BIG) award
Applicants who are conducting research at a for-profit institution, or at an institution outside of the United States
Four criteria are used to determine the merit of an application:
Qualifications of the applicant;
Quality of the proposed research;
Excellence of the research environment;
Likelihood that the project will advance the applicant's career in aging research.
The deadline for receipt of all Letters of Intent is December 16, 2013 at 5:00 p.m. EST. Please refer to the AFAR LOI instructions. Incomplete applications cannot be considered. All applications and supporting materials must be submitted through the website www.afar.org/grants/. The Letters of Intent will be reviewed by a committee. Applicants will be notified by January 31, 2014, and a subset of applicants will be invited to submit a full application by March 17, 2014 .
Investigators will be required to submit a brief narrative report on the progress of their research five months after the start date of the award. Final narrative and financial reports are required within three months following the end date of the award.
The award recipients are expected to attend the AFAR Grantee Conference which convenes AFAR grant recipients, mentors and leaders in the field to review and disseminate the research progress of the grantees and their findings. The meeting encourages networking, facilitates collaborations, and enhances the development of leadership.
Request for Applications: Leukemia & Lymphoma Society Screen to Lead Program
The Leukemia & Lymphoma Society (LLS) is sponsoring and issuing this Request for Applications (RFA) from qualified academic laboratories for drug discovery support specifically directed towards medicinal chemistry and/or drug target screening in hematological malignancies. LLS recognizes a significant need for investigators to receive resources for high-throughput screening and optimization of small molecules into drug-like compounds suitable for in vivo testing in a disease-relevant model that can be used for further preclinical proof-of-concept testing of the new drug target. Last year, the first year of this new funding mechanism, 6 projects were chosen for funding by an acclaimed peer review panel. This year, new laboratories/projects will be selected to participate in this model of collaboration whereby LLS, grantee, sponsoring institution and appropriate contract service organizations (CROs) or core facilities at academic institutions work together to develop compounds with the potential to change the standard of care for patients with blood cancer. Continued funding/sponsorship will be contingent on available funds and assessments of progress toward the goals outlined in each individual proposal accepted by LLS.
The goal of this RFA is the development of small molecule for in vivo proof of concept studies in disease relevant animal models for hematological malignancies. Proposals should include strong scientific rationale for a new drug target in a hematological malignancy; provide information to assess existing intellectual property or the potential for novel chemical space; demonstrate or explain how a screening assay can be developed to accommodate a high volume of compounds; or indicate how a tractable lead compound can be further developed.
Investigators at academic laboratories are eligible to apply. Investigators must demonstrate that their research environment is equipped and suitable for aspects of the work plan that would be carried out at their facility or in their lab rather than at a CRO. Collaborations between multiple investigators to strengthen the work proposed will be considered favorably, but are not a requirement. Applicants need not be United States (U.S.) citizens nor associated with a U.S.-based institution. Applicants should hold a Ph.D., M.D., D.V.M. or equivalent degree.
APPLICATION and AWARD INFORMATION
LLS plans to sponsor several awards during this year of this program. It is anticipated that each project will be unique and the cost of each work plan variable, depending on the nature of the work required. For this reason, applicants will need to submit a proposed work plan (subject to modification by LLS and collaborators upon review) and a proposed budget with justification for its relationship to the work plan. These factors will be evaluated as part of the peer review application process. As collaborators in CROs or core facilities may conduct the greater portion of the work, LLS will coordinate the appropriate contracting for services according to the work plan. LLS will work with applicants to determine where the work should be conducted and help to manage the process. For any budgeted line items that are specifically related to the PI, for work conducted in their laboratory, indirect costs will be capped at 11.1%. Any new intellectual property created through this collaboration shall be owned and managed by the academic institution. LLS and CRO subcontractors shall assign all ownership rights to the institution. LLS will put in place, as it does with all its grants, an IP policy that must be executed by the researcher and researcher's academic institution at the time the application is submitted.
Applicants should include the following in their application:
Scientific rationale for novel target in hematologic malignancies and summary of supportive data;
Characterization of existing compounds, where appropriate;
A summary of the intellectual property landscape (to the best of knowledge) on the target/chemical space;
Description of unmet medical need, i.e., what therapeutic deficiency will this new drug target address; and
Capabilities of support from laboratory (i.e., describing the level of throughput for assays applicants propose to run in their laboratories)
APPLICATION FORMAT and SUBMISSION
Application templates are web-based and may be obtained on our website at: http://lls.fluxx.io under Screen to Lead Program. Applications are restricted to the capacity of the web forms. The form for budgets allows multi-year entries but only the first year is considered for this award. Please include only costs associated with your institution. Any CRO costs, if needed, will be determined by LLS and added to your budget. If you have had prior discussions with a CRO and have a budget estimate, you are welcome to upload this under the appropriate section but no other supporting documentation is allowed except the signed IP policy which is part of the RFA and must be included with your application.
The cut off for the receipt of applications is on the following date/time schedule:
Deadline: December 15, 2013, 3:00 p.m., ET
Scientific Peer Review Committee: April 2014
Notification of Awards: May 30, 2014
Anticipated Funding Start Date: October 2014
DESCRIPTION of PEER REVIEW PROCESS
Each application will undergo a thorough review that consists of two parts. There will be an internal review by LLS Research staff for compliance with guidelines, eligibility, and responsiveness of the project to the RFA. The internal review may involve additional requests for more detailed information on the project and direct discussions between the PI and LLS Research staff regarding the proposal to assess the appropriateness of the project.
There will be a second review hosted by LLS that is a more extensive external peer review by experts in drug discovery and development, medicinal chemistry, and hematological malignancies.
The application will be assessed upon the following criteria:
Scientific Rationale and Supportive Data
Unmet Medical Need/Scientific Impact
Research Plan & Feasibility
Resources & Qualifications of the PI
Michael J. Fox Foundation for Parkinson's Research Target Validation Program
Fall 2014 Review Cycle
Informational Conference Call*: March 26, 2014 at 12pm US ET
Pre-proposals Due: May 28, 2014 – 6pm US ET
Full Proposal Invitations: June 18, 2014
Full Proposals Due (by invite only): August 6, 2014 – 6pm US ET
Anticipated Award Announcement: October 2014
Anticipated Funding: November 2014
*MJFF will hold a 45-minute conference call on the dates and times listed above to clarify and explain the goals of this funding initiative and answer applicant questions. To participate in the call and receive call-in details, please RSVP via email to firstname.lastname@example.org.
The Target Validation program supports work to determine whether manipulation of a defined biological target provides a disease-relevant beneficial outcome in a whole animal, mammalian model of PD. MJFF does not have any pre-conceived preferences for particular targets submitted to the Target Validation program. However, we recommend applicants consider the following:
The target should be clearly defined, such as:
A specific gene
A structural/functional feature of a protein (e.g., its enzymatic activity, protein conformation or ability to interact with other proteins)
Proposals seeking to manipulate global pathways without a clear target are not encouraged
Applicants may propose a variety of methods to manipulate a target, including but not limited to:
Use of pharmacological tools
Supporting data/explanation of the proposed pharmacological tool must be addressed in the body of the proposal.
Parameters that should be discussed include:
Selectivity for the target of interest
Pharmacokinetic/Pharmacodynamic measures that have been/will be assessed
Measures of target engagement
Use of biologic strategies such as:
Viral vector-mediated gene delivery, etc.
In Vivo Models
Applicants may also propose use of models appropriate for the target proposed including:
Previously established genetically engineered animal models including:
Knockout models where the target/gene of interest is deleted
Transgenic models whereby the target/gene of interest is over-expressed
Investigators should proposed to examine PD-relevant features or sensitivity to PD-associated factors during the course of their studies
Proposals may include intermediate tests using in vitro, ex vivo and/or model organisms (e.g., Drosophila, C. elegans) to optimize the ideal target manipulation strategy
These proposals must ultimately include within the grant funding period an evaluation of the target manipulation in a whole-animal mammalian model of PD
Note: The following types of proposals are not appropriate for the Target Validation program:
Proposals focused on new target identification and proposals testing cellular transplantation approaches.
Proposals seeking to generate new genetic (knockin, knockout, transgenic) models
Investigators seeking guidance to develop new models around their target are encouraged to contact email@example.com
Applicants seeking support for therapeutic development should submit to the Therapeutic Pipeline Program or contact MJFF research staff for guidance.
MJFF will commit up to $10 million to the Edmond J. Safra Core Programs for PD Research with the intention to support multiple awards. The Target Validation program supports two-year grants up to $250,000 total costs inclusive of both direct and indirect costs. The total annual direct costs cannot exceed $100,000. No more than 25% (Academic institutions) or 10% (for-profit organizations) of the direct costs may go to indirect costs.
Applications may be submitted by:
U.S. and non-U.S. biotechnology/pharmaceutical companies or other for-profit entities, either publicly or privately held,
U.S. and non-U.S. entities, public and private non-profit entities, such as universities, colleges, hospitals, laboratories, units of state and local governments, and eligible agencies of the federal government.
Post-doctoral fellows are NOT eligible to apply as Principal Investigators to the Target Validation program.
National Blood Foundation Scientific Research Grants Program
All applications must be received at the NBF office by 11:59 pm ET, December 31, 2013. Extensions will not be granted.
Funds are raised annually from corporations, blood centers, foundations and individuals by the NBF for the National Blood Foundation Research and Education Trust Fund (NBFRET) and the NBF. The NBF and NBFRET, which are 501(c)(3) organizations, provide grants for scientific research in the field of transfusion medicine and cellular therapies and support educational initiatives that benefit this community. Since 1985, the NBF has distributed approximately $8 million to 182 early-career scientists. The National Blood Foundation annually awards grants for one or two-year research projects, with a maximum award per grant of $75,000.
NBF is pleased to announce the availability of funding in 2014 for scientific research projects related to transfusion medicine and cellular therapies. NBF will award grants for investigator-initiated original research in all aspects of blood banking, transfusion medicine and cellular therapies. NEW in 2014, patient blood management is introduced as a research content area.
Important areas of research for the grant program include:
Alloimmunization, immune modulation, and tolerance
Animal models for the study of graft-vs-host disease
Biology of autoimmune hemolytic anemia
Autologous and allogeneic stem cell transplants
Detection of residual disease following stem cell transplants
Effects of growth factors in vitro and in vivo
Biochemistry of coagulation factors
Blood group serology
Biochemistry of red cell antigens
Molecular genetics of the blood groups
Studies on Lyme disease, West Nile Virus, SARS and babesiosis and other emerging diseases
Effect of allogeneic transfusion in HIV-infected and immunocompromised patients
Improved detection of transfusion - transmitted diseases
Cell separation, cell culture or expansion studies for cell therapy applications
Development of novel cell therapies or assays to measure cell viability or function
Pilot studies in regenerative medicine
Studies on mechanisms or roles of cells in stem cell transplantation
Studies on cytokines or growth factors involved in stem cell differentiation
NEW!! PATIENT BLOOD MANAGEMENT
Treatment of pre-admission anemia and bleeding tendencies; Intraoperative/postoperative blood recovery; Surgical hemostasis; Appropriate indications for transfusion; Changing physician behaviors; Blood utilization review.
Grants applications are evaluated on the basis of their scientific merit, relevance to and impact on transfusion medicine, focus and appropriateness to the scope of funding, and likelihood of yielding meaningful data.
An applicant must be a doctor (MD or PhD), medical technologist, transfusion medicine or cellular therapies professional. All applicants will be considered regardless of age, race, gender, national origin or religion.
The NBF accepts national and international applicants who are ideally no more than five years post-doctoral training.
Applications for research into innovative and new projects are a priority.
Emphasis is given to applicants who have not previously received an NBF grant.
No candidate is eligible to receive more than two NBF grants for separate projects.
No particular project can be funded more than once.
An application for the same project may be submitted up to three times if not already NBF funded.
Awards will not be made to increase the funding available for currently funded research projects. NBF grants are intended to provide "seed" funding that allows the principal investigator to enhance preliminary data. This data may then be useful in applying for larger grants.
All applicants will be charged an application fee of $150 except for principal investigators who are individual members of the AABB. AABB institutional membership does not qualify. To become an AABB member, please contact AABB's Membership Services at +1.301.215.6489 or firstname.lastname@example.org.
Contact NBF at +1.301.215.6552 or email@example.com.